Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

The FDA Friday approved pemigatinib (Pemazyre), a selective fibroblast growth factor (FGFR) inhibitor, to treat adults who have relapsed or refractory (R/R) myeloid/lymphoid neoplasms (MLNs) with ...

The approval was based on data from the phase 2 FIGHT-203 study, which included 28 patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. The Food and Drug ...

The prognosis for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements is poor, and treatment options are limited. In a phase II study of these patients, the overall complete response ...

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. The Food and Drug Administration (FDA) ...

Analysis of >40 subtypes of lymphoid blood cancer tracked by the UK Haematological Malignancy Research Network reveals wide incidence and survival variation, but distinct gains in survival since ...

Rosai-Dorfman-Destombes disease (RDD) is a rare, benign histiocytic disorder, most often involving lymph nodes but showing ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and ...